Pure Bioscience, Inc. (PURE) Reports Q3 EPS of $0.00
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street futures subdued as tech wobbles again; Tesla gains
- Oil heads for weekly gain with focus on Middle East supply
- U.S. producer prices rise by 1.3% month-on-month in September
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise, dollar set for weekly loss after yields drop
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
December 15, 2025 4:05 PM ESTEL CAJON, Calif.--(BUSINESS WIRE)-- PURE Bioscience, Inc. (OTCQB: PURE) (PURE, the Company or we), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal... More



